-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A paper The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer published in Nature showed that the combination of immunotherapy with chemotherapy and targeted drugs is expected to improve the transformation of patients with HER2-positive gastric cancer.
Return
.
The study is based on an interim analysis of a phase III clinical trial, which has prompted the U.
S.
Food and Drug Administration (FDA) to approve the clinical use of the therapy
.
About 20% of patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma will overexpress human epidermal growth factor receptor-2 protein (HER2)
.
For more than ten years, the standard first-line therapy has been a combination of anti-HER2 antibody trastuzumab (trastuzumab) and chemotherapy
.
As part of the KEYNOTE-811 Phase III clinical trial, Yelena Janjigian of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College and colleagues evaluated the additional energy band of pembrolizumab (pembrolizumab).
What are the benefits of treatment
.
Pembrolizumab is an antibody that helps the immune system recognize and attack tumor cells
.
The trial counted the efficacy data of 264 enrolled patients
.
The team found that adding pembrolizumab to trastuzumab and chemotherapy can shrink tumors in some patients and induce a complete response (temporary complete remission)-the complete response rate can be increased from 3.
1% to 11.
3 %; The proportion of patients with the best response has also increased significantly
.
In view of the good results of the trial, the authors recommend that the same triple therapy be tested in early patients of the disease
.
In the future, the trial will continue to monitor the impact of this combination therapy on patient survival
.
In the effective population, the target lesion size is based on the best percentage change from baseline
.
Source: Kim et al.
©NatureNature | doi: 10.
1038/s41586-021-04161-3
Return
.
The study is based on an interim analysis of a phase III clinical trial, which has prompted the U.
S.
Food and Drug Administration (FDA) to approve the clinical use of the therapy
.
About 20% of patients with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma will overexpress human epidermal growth factor receptor-2 protein (HER2)
.
For more than ten years, the standard first-line therapy has been a combination of anti-HER2 antibody trastuzumab (trastuzumab) and chemotherapy
.
As part of the KEYNOTE-811 Phase III clinical trial, Yelena Janjigian of Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College and colleagues evaluated the additional energy band of pembrolizumab (pembrolizumab).
What are the benefits of treatment
.
Pembrolizumab is an antibody that helps the immune system recognize and attack tumor cells
.
The trial counted the efficacy data of 264 enrolled patients
.
The team found that adding pembrolizumab to trastuzumab and chemotherapy can shrink tumors in some patients and induce a complete response (temporary complete remission)-the complete response rate can be increased from 3.
1% to 11.
3 %; The proportion of patients with the best response has also increased significantly
.
In view of the good results of the trial, the authors recommend that the same triple therapy be tested in early patients of the disease
.
In the future, the trial will continue to monitor the impact of this combination therapy on patient survival
.
In the effective population, the target lesion size is based on the best percentage change from baseline
.
Source: Kim et al.
©NatureNature | doi: 10.
1038/s41586-021-04161-3
